Citation tools
"Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry." Journal of Nuclear Medicine
63.8
(2022):
1199-1207.
Web. 23 April. 2025.